
Two laws promoting pediatric drug studies have provided clinicians with a wealth of data on drug efficacy and safety in children, but a new report from the Institute of Medicine suggests that several improvements are needed before they are reauthorized this year. Read how the findings could help Congress strengthen the scope of the current laws to continue critical advances in drug studies that benefit the nation?s children.

